CD274 and neoplasm: Further insight into the role of PD-L1 and PD-1 in the tumor microenvironment could allow the identification of more appropriate biomarkers predictive of clinical efficacy to PD-1/PD-L1-targeted therapy necessary to ensure patients receive the maximum clinical benefit whilst avoid immune-related adverse effects (24, 29), pseudoprogression and hyperprogression (33).